다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (ARQT) 뉴스

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ARQT

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/04	05:00	GlobeNewswire Inc.	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/30	05:00	GlobeNewswire Inc.	Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/10	21:00	GlobeNewswire Inc.	Arcutis Appoints David Topper as Chief Financial Officer	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/06	05:00	GlobeNewswire Inc.	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/01	20:00	GlobeNewswire Inc.	Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/28	21:00	GlobeNewswire Inc.	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/11	21:00	GlobeNewswire Inc.	Arcutis Promotes Todd Tucker to Chief Human Resources Officer	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/11	05:00	GlobeNewswire Inc.	Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/10	06:00	GlobeNewswire Inc.	New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/07	07:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/07	07:09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/07	07:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/06	06:00	GlobeNewswire Inc.	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	07:47	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	07:42	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	07:40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	06:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	06:00	GlobeNewswire Inc.	Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/04	22:00	GlobeNewswire Inc.	Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/02	06:11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/02	06:06	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/01	07:00	GlobeNewswire Inc.	Arcutis to Present at the TD Cowen 44th Annual Health Care Conference	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	13:30	GlobeNewswire Inc.	Arcutis Announces Pricing of $150 Million Public Offering	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06:54	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06:21	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06:10	GlobeNewswire Inc.	Arcutis Announces Proposed Public Offering	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/29	06:00	GlobeNewswire Inc.	Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/28	06:34	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/02/27	21:48	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ARQT	Arcutis Biotherapeutics Inc

검색 관련기사 보기:NASDAQ:ARQT

1 2 3 4 5 6 7 8 9 10 다음 >>

Invesco QQQ Trust Series 1

Health Care Select Sector

Energy Select Sector SPDR

Financial Select Sector

US Dollar vs Yen

JP Morgan Chase

American Express

Bank of America

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관